FN2 Earnings Intelligence
Kymera Therapeutics, Inc. income statement (quarterly)
Kymera Therapeutics, Inc. (KYMR) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $90 | $335.8 | $112.9 | $144.1 | $124.5 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $22.1 | $11.5 | $2.8 | $34.4 | $65 |
| % Growth | - | - | - | - | - |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| % Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA | -$72.4 | -$82.9 | -$90.4 | -$82.1 | -$74 |
| % Margin | -327.5% | -722.0% | -3,271.4% | -239.0% | -113.9% |
| Net Income | -$65.6 | -$76.6 | -$82.2 | -$69.2 | -$61.2 |
| % Margin | -296.7% | -667.6% | -2,973.0% | -201.5% | -94.2% |
| Diluted EPS | -$0.82 | -$0.95 | -$0.94 | -$0.71 | -$0.62 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | -$79.2 | - | - | -$88.8 | - |
| CapEx | $0.5 | - | - | $0.4 | - |
| Free Cash Flow | -$79.6 | - | - | -$89.3 | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $22.1 | $11.5 | $2.8 | $34.4 | $65 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| EBITDA | -$72.4 | -$82.9 | -$90.4 | -$82.1 | -$74 |
| Net Income | -$65.6 | -$76.6 | -$82.2 | -$69.2 | -$61.2 |
| Diluted EPS | -$0.82 | -$0.95 | -$0.94 | -$0.71 | -$0.62 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $90 | $335.8 | $112.9 | $144.1 | $124.5 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$79.2 | - | - | -$88.8 | - |
| Capital Expenditure | $0.5 | - | - | $0.4 | - |
| Free Cash Flow | -$79.6 | - | - | -$89.3 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA Margin | -327.5% | -722.0% | -3,271.4% | -239.0% | -113.9% |
| Net Margin | -296.7% | -667.6% | -2,973.0% | -201.5% | -94.2% |
| FCF Margin | -360.3% | - | - | -259.8% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the KYMR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.